Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7743860 | 0.93 | CTSK (0.49) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL31127632 | 0.92 | CTSK (0.54) | CTSKCA1CA2CA7ATM | |
| SCHEMBL3378594 | 0.86 | CTSK (0.44) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL5196572 | 0.85 | CTSK (0.45) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL12290180 | 0.85 | CTSK (0.45) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL211054 | 0.85 | CTSK (0.45) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL211053 | 0.85 | CTSK (0.45) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL11137176 | 0.84 | CTSK (0.44) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL1722623 | 0.83 | CTSK (0.50) | CTSKCA1CA2CA7ATM | |
| SCHEMBL29955586 | 0.83 | CTSK (0.50) | CTSKCA1CA2CA7ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| US-11512096-B2 | Seco macrolide compounds | SELVITA D.O.O. (HR) | 2022-11-29 | — | — | US | disclosed |
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SELVITA D.O.O. (HR) | 2021-07-01 | — | — | US | disclosed |
| US-10919910-B2 | Seco macrolide compounds | FIDELTA D.O.O. (HR) | 2021-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SEC61B, SEC16A, SEC61A1 | CTSK 1034/4885MAPT 3885/4885CA1 4884/4885 |
| US-11512096-B2 | Seco macrolide compounds | SEC61B, SEC16A, SEC61A1 | CTSK 1034/4885MAPT 3885/4885CA1 4884/4885 |
| US-10919910-B2 | Seco macrolide compounds | SEC61B, SEC16A, SEC61A1 | CTSK 1034/4885MAPT 3885/4885CA1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.